Navigation Links
Cancer Mortality Rates Experience Steady Decline
Date:8/12/2009

GRAND RAPIDS, Mich., Aug. 13 /PRNewswire/ -- The number of cancer deaths has declined steadily in the last three decades. Although younger people have experienced the steepest declines, all age groups have shown some improvement, according to a recent report in Cancer Research, a journal of the American Association for Cancer Research.

"Our efforts against cancer, including prevention, early detection and better treatment, have resulted in profound gains, but these gains are often unappreciated by the public due to the way the data are usually reported," said Eric Kort, M.D., who completed the study while employed as a research scientist at Van Andel Research Institute (VARI) in Grand Rapids, Mich.

Cancer mortality rates are usually reported as composite age-adjusted rates. These rates have been declining modestly since the 1990's. However, these statistics heavily emphasize the experience of the oldest Americans for whom mortality rates are the highest. As a result, trends emerging in younger Americans can be concealed.

As an alternative to age-adjustment, Kort examined cancer mortality rates stratified by age and found that for individuals born since 1925, every age group has experienced a decline in cancer mortality. The youngest age groups have experienced the steepest decline at 25.9 percent per decade, but even the oldest groups have experienced a 6.8 percent per decade decline.

The public often hears about incidence rates, which continue to rise across many cancer types, or mortality proportions, with the World Health Organization's assertion that death from cancer will surpass death from heart disease by 2010. Both these calculations are accurate, Kort said, but they ask the wrong question. In particular, the often-quoted WHO statistic can be misleading.

Richard Severson, Ph.D., a cancer epidemiologist and associate chair
'/>"/>

SOURCE Van Andel Institute
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 12, 2014 Ladies, it doesn't matter what ... Those who are looking for an affordable gown can ... occasion dresses) to get their dream items. Recently, the company ... length gowns . Along with that, it is also providing ... the special offer; the deadline of this promotion is July ...
(Date:7/11/2014)... According to new report "C4ISR ... expected to register a CAGR of 2.28% to ... market data tables and 76 figures spread through ... http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers will receive ... , The report provides market analysis of the ...
(Date:7/11/2014)... -- Reducing the number of deer in an area ... other tick-borne infections among people, new research indicates. ... to reduce human interactions with deer, infected nymphal ticks ... wrote. White-tailed deer are the primary host for ... The study included nearly all the permanent residents ...
(Date:7/11/2014)... Microbiology testing is a highly dynamic and rapidly ... expected to pose the biggest challenge to suppliers in ... to the ongoing spread of AIDS – still the ... factor leading to the upsurge of opportunistic infections, novel ... availability of immunosuppressants, among others. , Market maturity, ...
(Date:7/11/2014)... Datalogic brings a new and innovative scanner ... With their new Gryphon GD4400 and GM4400 ... devastating MRSA, which claimed 5,500 lives, becomes more preventable. ... and the Gryphon GM4400-HC 2D readers can scan nearly ... barcodes off of troublesome LCD monitors, smartphones, and other ...
Breaking Medicine News(10 mins):Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3
... highly effective in preventing the behavioral and academic problems ... a five-year study led by researchers at Lehigh Universitys ... and funded by the National Institute of Mental Health ... children aged 3 to 5 who have shown significant ...
... Diabetes patients could benefit from new research at the ... the intestine that can taste the sugar content of ... receptor that senses sugar and artificial sweeteners is not ... intestine. The discovery will open new avenues for the ...
... misinformation onlineconsequences could be deadly , The Internet ... to spread false ideas about HIV/AIDS, which could have ... paper in PLoS Medicine. , "It may seem remarkable ... is still denial that the virus is the cause ...
... with organ transplants, resigned to a lifetime of anti-rejection ... respite, say researchers at Lucile Packard Children,s Hospital and ... blood sample, the scientists have identified for the first ... small group of patients who beat the odds and ...
... were more likely to be uninsured or covered by ... report in the August issue of Archives of Otolaryngology-Head ... Laryngeal [voice box] cancer is diagnosed in nearly 10,000 ... is among the most common cancers in the upper ...
... STANFORD, Calif. - As U.S. policy experts continue to ... a new study from the Stanford University School of ... group of patients reduce their overall risk of heart ... a cost-effective way. , Case management makes use of ...
Cached Medicine News:Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 2Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 3Health News:Discovery of 'sugar sensor' in intestine could benefit diabetes 2Health News:HIV denialists spread misinformation online -- consequences could be deadly; and more 2Health News:Study provides hope that some transplant patients could live free of anti-rejection drugs 2Health News:Study provides hope that some transplant patients could live free of anti-rejection drugs 3Health News:Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 2Health News:Stanford study highlights cost-effective method of lowering heart disease risks 2Health News:Stanford study highlights cost-effective method of lowering heart disease risks 3
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... , SOUTH SAN FRANCISCO, Calif., July 8 Rigel Pharmaceuticals, ... Company plans to host a conference call on Thursday, July ... Members of Rigel,s senior management team and the principal investigator ... 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the ...
... OAKS, Calif., July 7 Amgen (Nasdaq: ... head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in ... advanced breast cancer met its primary and secondary endpoints ... was demonstrated for both delaying the time to the ...
Cached Medicine Technology:Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8